Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
NeuTec Pharma
ClinicalTrials.gov Identifier:
NCT00217815
First received: September 15, 2005
Last updated: July 14, 2008
Last verified: July 2008
  Purpose

The study hypothesis is that the addition of Mycograb to docetaxel will improve outcome in advanced carcinoma of the breast.


Condition Intervention Phase
Cancer of the Breast
Drug: Mycograb, Docetaxel
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase Ib, Pharmacokinetic, Multiple Center, Open Label Study Evaluating the Safety and Efficacy of Mycograb Administered IV in Combination With Docetaxel in Metastatic or Recurrent Breast Cancer Patients

Resource links provided by NLM:


Further study details as provided by NeuTec Pharma:

Primary Outcome Measures:
  • Impact on tumour size when compared to historical controls

Secondary Outcome Measures:
  • Safety data
  • Pharmacokinetics data

Estimated Enrollment: 20
Study Start Date: September 2005
Estimated Study Completion Date: October 2006
Detailed Description:

Combination therapies that incorporate new agents have demonstrated the potential to improve outcome for patients with metastatic breast carcinoma. Docetaxel has been shown to be a very active drug in breast cancer, and anthracycline-based chemotherapy combinations represent the most active form of therapy generating objective response rates of between 40-70%. Mycograb® was most effective in breast carcinoma cell lines in combination with cisplatin, docetaxel and anthracyclines (doxorubicin, daunorubicin).

We propose that Mycograb® binds to hsp90, inhibiting hsp90 chaperone functioning and resulting in the destabilization of key proteins including estrogen/steroid receptors, nitric oxide synthase, ras1, MAP (Mitogen-activated protein) kinase, Src, Erb-B2,(erythroblastic leukemia viral oncogene homolog 2) HER(human estrogen receptor) kinases and EGFR (epidermal grown factor receptor). Over expression of HER2 receptors are observed in malignancies such as breast cancer and reportedly have been associated with resistance to chemotherapeutic agents. Both maturing and fully mature forms of the receptor depend on hsp90 association for stability. Inhibition of hsp90 function down regulates AKT kinase and Src kinase which are non-receptor kinase. Therefore, Mycograb® may be of use in estrogen dependent and hormone independent breast cancers.

Mycograb® has been demonstrated to have anti-tumor activity in cell culture. The 50% cytotoxicity of Mycograb® on its own is 50 Combination therapies that incorporate new agents have demonstrated the potential to improve outcome for patients with metastatic breast carcinoma. Docetaxel has been shown to be a very active drug in breast cancer, and anthracycline-based chemotherapy combinations represent the most active form of therapy generating objective response rates of between 40-70%. Mycograb® was most effective in breast carcinoma cell lines in combination with cisplatin, docetaxel and anthracyclines (doxorubicin, daunorubicin).

We propose that Mycograb® binds to hsp90, inhibiting hsp90 chaperone functioning and resulting in the destabilization of key proteins including estrogen/steroid receptors, nitric oxide synthase, ras1, MAP kinase, Src, Erb-B2, HER kinases and EGFR. Overexpression of HER2 receptors are observed in malignancies such as breast cancer and reportedly have been associated with resistance to chemotherapeutic agents. Both maturing and fully mature forms of the receptor depend on hsp90 association for stability. Inhibition of hsp90 function down regulates AKT kinase and Src kinase which are non-receptor kinase. Therefore, Mycograb® may be of use in estrogen dependent and hormone independent breast cancers.

Mycograb® has been demonstrated to have anti-tumor activity in cell culture. The 50% cytotoxicity of Mycograb® on its own is 50 µg/ml (MCF7 [Breast cancer cell line designation]). Mycograb® in combination with docetaxel, doxorubicin and cisplatin and Herceptin increased the cytotoxicity in breast cancer cells.

It is appropriate to evaluate the apparent tumor response and survivor benefits resulting from the addition of Mycograb® to a docetaxel containing chemotherapy regimen in metastatic or recurrent breast cancer patients.

(MCF7). Mycograb® in combination with docetaxel, doxorubicin and cisplatin and Herceptin increased the cytotoxicity in breast cancer cells.

It is appropriate to evaluate the apparent tumor response and survivor benefits resulting from the addition of Mycograb® to a docetaxel containing chemotherapy regimen in metastatic or recurrent breast cancer patients.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must be female between the ages of 18 to 70 years old.
  2. Patients must have histologically or clinically confirmed metastatic and/or recurrent breast cancer amenable to treatment with docetaxel.
  3. Patients must have presence of at least one uni-dimensional measurable lesion with minimal lesion size > 20 mm at the largest diameter.
  4. Patients may have had one previous chemotherapy regimen and must not have received prior chemotherapy with docetaxel.
  5. Patients must have been off all hormonal therapy for at least 2 weeks prior to initiation of therapy.
  6. Patients must have been off all chemotherapy or radiotherapy regimens for at least 4 weeks prior to initiation of chemotherapy.
  7. Patients must have a life expectancy of at least 6 months.
  8. Patients must have a ECOG status of 0, 1 or 2.
  9. Patients must be willing to complete all procedures and visits as outlined in the protocol.
  10. Patients must sign an informed consent form.
  11. Patients must have negative blood test for HIV and hepatitis B and C.
  12. Female patients of child bearing potential should use an effective method of contraception.

Exclusion Criteria:

  1. Patients with brain or meningeal metastases.
  2. Patients whose only measurable lesion is in the bone.
  3. Patients with clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, respiratory, neurologic, psychiatric, immunologic, gastrointestinal, hematologic, metabolic or any other condition or laboratory abnormality that in the opinion of the investigator makes the patient unsuitable for participation in the study.
  4. Patients with history of seizure disorder.
  5. Patients who have received treatment with any other investigational drug within the preceding one month.
  6. Patients who are pregnant or breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00217815

Locations
Poland
Chemotherapie Clinic of Medical University Lodz
Lodz, Pabianicka, Poland, 93-513
Serbia
Clinical Hospital Centre Bezanijska Kosa
Bezanijska Kosa bb, Belgrade, Serbia, 11000
Institute For Oncology and Radiology of Serbia
Pasterova 14, Belgrade, Serbia, 11000
Sponsors and Collaborators
NeuTec Pharma
Investigators
Principal Investigator: Anna Pluzanska, MD University of Lodz
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00217815     History of Changes
Other Study ID Numbers: NTP/ONC/001
Study First Received: September 15, 2005
Last Updated: July 14, 2008
Health Authority: Poland: Ministry of Health

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014